Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE M/S. Reportstack
NEW YORK, LONDON, BERLIN and PARIS, July 9, 2014 /PRNewswire/ --
Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation is a new market research report announced by Reportstack. Despite mostly targeting established molecules, the psoriasis pipeline is showing a high level of innovation in first-in-class molecules, including novel angiogenic drugs, growth factors, chaperone proteins and cytokines, says a new report from business intelligence provider Reportstack.
The latest report from Reportstack states that first-in-class programs constitute an estimated 27% of the entire psoriasis pipeline, and are predominantly composed of targeted therapies, including cytokine and receptor modulators, nuclear receptor modulators and intracellular kinase inhibitors. Analyst says: "There are several novel therapies targeting first-in-class T cell antigens, thanks to a growing understanding of the signaling pathways underlying the psoriasis pathophysiology, in which T cells have been shown to play a substantial role in disease progression."
Therapies that can selectively modulate specific subsets of immune cells, without compromising the entire immune system, have become increasingly desirable, according to research. One such program is Tregalizumab, a humanized Cluster of Differentiation (CD) 4-specific monoclonal antibody. The Analyst further continue: "In contrast to other anti-CD4 antibodies, Tregalizumab is able to activate the suppressive properties of regulatory T cells. It is currently in Phase II clinical trials for the treatment of rheumatoid arthritis and in Preclinical development for treating psoriasis."
Research states that although no preclinical or clinical efficacy data has been disclosed for the antibody, it has been involved in a lucrative co-development deal worth $480 million between Biotest and Abbott Laboratories. Several promising first-in-class therapies can selectively modulate specific subsets of immune cells without compromising the entire immune system. In particular, biologics that target a subset of T cells, which are strongly implicated in autoimmune pathophysiology, could allow for specificity of immune suppression and thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have demonstrated superiority over currently established therapies in achieving advanced clinical endpoints.
Other promising psoriasis therapies are targeting novel angiogenic signaling molecules at the psoriatic plaque level, as topical therapies. This has been validated in a small scale, double-blind and randomized clinical study, according to analysts. "With further validation in larger scale clinical studies, insulin receptor substrate-1 inhibitors may prove to be a novel localized therapy for psoriasis, which can be used in conjunction with systemic treatments," analysts conclude. To know more about more details kindly visit http://www.reportstack.com/product/160772/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation.html
Other related pharma industry reports :
Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of pharma and healthcare market research.
Senior Marketing Executive
Phone: +1 888-789-6604
Follow us: https://twitter.com/reportstack
©2012 PR Newswire. All Rights Reserved.